Latest Mitsubishi Tanabe Ph (MTZXF) Headlines
Post# of 3
Posted On: 03/10/2014 5:34:03 PM
Latest Mitsubishi Tanabe Ph (MTZXF) Headlines
Concise Analysis of the Future Prospects of Global Personalized Medicine Market
M2 - Tue Mar 04, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/zpctsr/future_prospects) has announced the addition of the "Concise Analysis of the Future Prospects of Global Personalized Medicine Market" report to their offering. Over the years, the Global Personalized Medicine market has been witnessing the emergence of various tools and technologies from the reputed vendors. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Further, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 for predicting the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Co. - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Danaher Corp. - Eli Lilly and Co. - Evotec AG - F. Hoffmann-La Roche Ltd. - GE Healthcare Ltd. - Genelex Corp. - GlaxoSmithKline plc - Hologic Inc. - Johnson & Johnson - Laboratory Corporation of America Holdings - Life Technologies Corp. - Merck KGaA - Mitsubishi Tanabe Pharma Corp. - Myriad Genetics Inc. - Novartis AG - Novartis AG - PerkinElmer Inc. - Pfizer Inc. - Pfizer Inc. - Quest Diagnostics Inc. - Sanofi S.A. - Sanofi S.A. - Siemens Healthcare - Sigma-Aldrich Corp. - Takeda Pharmaceutical Co. Ltd. - Teva Pharmaceutical Industries Ltd. - Thermo Fisher Scientific Inc. - Transgenomic Inc. For more information visit http://www.researchandmarkets.com/research/zp..._prospects
MediMabs Announces the Appointment of Two New Members of the Board of Directors
Marketwire - Thu Feb 20, 10:52AM CST
Ms. Sarita Benchimol, the President and Chief Executive Officer of MediMabs Inc., is pleased to announce the election to the MediMabs Board of Directors of Dr. Randal Chase PhD and Mr. R Martin Wong CPA, CA. Both individuals were elected at the company's shareholder meeting and will be joining the existing board of directors, which includes Dr. Phil Gold CC, OQ, MD, PhD, FRSCopyright, FRCPCopyright, MACP, Dr. Claudio Cuello OC, MD, DSc, FRSCopyright, Mr. Miguel Madanes Eng., and Ms. Sarita Benchimol MSc.
General Anxiety Disorder - Pipeline Review, H2 2013
M2 - Tue Jan 28, 3:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/45w2z8/general_anxiety) has announced the addition of the "General Anxiety Disorder - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for General Anxiety Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for General Anxiety Disorder. General Anxiety Disorder - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for General Anxiety Disorder. - A review of the General Anxiety Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the General Anxiety Disorder pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to Buy - Identify and understand important and diverse types of therapeutics under development for General Anxiety Disorder. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding General Anxiety Disorder pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - Edgemont Pharmaceuticals - H. Lundbeck - Mitsubishi Tanabe Pharma Corporation - Rottapharm|Madaus For more information visit http://www.researchandmarkets.com/research/45...al_anxiety About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Market Research: Depression - Pipeline Review, H2 2013
M2 - Fri Dec 06, 3:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/q2dd65/depression) has announced the addition of the "Depression - Pipeline Review, H2 2013" report to their offering. 'Depression - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Depression, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Depression. Scope - A snapshot of the global therapeutic scenario for Depression. - A review of the Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Depression pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH AstraZeneca PLC GlaxoSmithKline plc Daiichi Sankyo Company, Ltd Taisho Pharmaceutical Co., Ltd. Takeda Pharmaceutical Company Limited Neurocrine Biosciences, Inc. Aphios Corporation Eisai Co., Ltd. H Lundbeck A/S Mitsubishi Tanabe Pharma Corporation Pfizer Inc. Sigma-Tau S.p.A. Addex Pharmaceuticals FAES Farma SA Anavex Life Sciences Corp. Karo Bio KunWha Pharmaceutical Co., Ltd. Newron Pharmaceuticals S.p.A. M et P Pharma AG Angelini Group Domain Therapeutics For more information visit http://www.researchandmarkets.com/research/q2dd65/depression About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Market Research: Secondary Hyperparathyroidism - Pipeline Review, H2 2013
M2 - Tue Dec 03, 3:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/db8lm5/secondary) has announced the addition of the "Secondary Hyperparathyroidism - Pipeline Review, H2 2013" report to their offering. 'Secondary Hyperparathyroidism - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Secondary Hyperparathyroidism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Secondary Hyperparathyroidism. Scope - A snapshot of the global therapeutic scenario for Secondary Hyperparathyroidism. - A review of the Secondary Hyperparathyroidism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Secondary Hyperparathyroidism pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Secondary Hyperparathyroidism. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Amgen Inc. Nektar Therapeutics Astellas Pharma Inc. Mitsubishi Tanabe Pharma Corporation OPKO Health, Inc. NPS Pharmaceuticals, Inc. Deltanoid Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/db8lm5/secondary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Invokana (Type 2 Diabetes) - Forecast and Market Analysis to 2022
M2 - Thu Nov 28, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/wvj6kv/invokana_type_2) has announced the addition of the "Invokana (Type 2 Diabetes) - Forecast and Market Analysis to 2022" report to their offering. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians' efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs. On March 29, 2013, the FDA approved Johnson & Johnson's Invokana (canagliflozin), the first-to-the-US-market SGLT-2 inhibitor for treatment of type 2 diabetes. Invokana is in-licensed from Mitsubishi Tanabe Pharma. Invokana's mechanism of action employs the inhibition of SGLT-2, a low-affinity, high-capacity glucose cotransporter that is almost exclusively expressed in the kidney cortex. Inhibition of SGLT-2 has been shown to block the body's capacity to reabsorb glucose via the kidney, leading to glucose elimination in the urine and a reduction in blood glucose levels. Scope - Overview of type 2 diabetes, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Invokana including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Invokana for the top ten countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China. Reasons to Buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of Invokana performance Key Topics Covered 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Invokana (canagliflozin) 7 Appendix For more information visit http://www.researchandmarkets.com/research/wv...ana_type_2 About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Covagen and Tanabe Research Laboratories Expand Strategic Research Collaboration for Development of Bispecific FynomAbs
PR Newswire - Thu Nov 21, 12:30AM CST
Covagen and Tanabe Research Laboratories U.S.A, Inc. (TRL), a fully owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), today announced that they expanded their strategic research collaboration. MTPC and TRL have nominated a first bispecific FynomAb for formal preclinical development which triggered an undisclosed milestone payment. MTPC and TRL also exercised an option for a second bispecific FynomAb program based on the parties' research and licensing agreement signed in October 2012. Under the agreement, Covagen will use its proprietary Fynomer-antibody platform to generate bispecific antibodies (FynomAbs) against a second target pair selected by TRL and MTPC.
Inflammatory Bowel Disease - Pipeline Review, H2 2013
M2 - Tue Nov 19, 3:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/g29c7q/inflammatory) has announced the addition of the "Inflammatory Bowel Disease - Pipeline Review, H2 2013" report to their offering. 'Inflammatory Bowel Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Inflammatory Bowel Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease. Scope - A snapshot of the global therapeutic scenario for Inflammatory Bowel Disease. - A review of the Inflammatory Bowel Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Inflammatory Bowel Disease pipeline on the basis of route of administration and molecule type. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Inflammatory Bowel Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Inflammatory Bowel Disease pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Key Topics Covered: Introduction Inflammatory Bowel Disease Overview Therapeutics Development Companies Involved in Inflammatory Bowel Disease Therapeutics Development Inflammatory Bowel Disease - Therapeutics Assessment Drug Profiles Appendix Companies Mentioned - 4SC - AlbireoPharma - Addex Pharmaceuticals - Basilea Pharmaceutica - Biotec Pharmacon - Compugen - Emergent BioSolutions - Eisai - Ferring Pharmaceuticals - GlaxoSmithKline - Indus Biotech Private Limited - Inotek Pharmaceuticals - Jenrin Discovery - Johnson & Johnson - KYORIN Pharmaceutical - Karo Bio - Lycera - Morria Biopharmaceuticals - Mitsubishi Tanabe Pharma - N30 Pharmaceuticals - Nephrx Corporation - Ono Pharmaceutical - Onyx Pharmaceuticals - PepTcell Limited - Paratek Pharmaceuticals - RaQualia Pharma - Rigel Pharmaceuticals - Santarus, Inc. - Synergy Pharmaceuticals - TiGenix NV - Upsher-Smith Laboratories - VentiRx Pharmaceuticals - Ventria Bioscience - Vitae Pharmaceuticals - Zealand Pharma A/S - iCo Therapeutics For more information visit http://www.researchandmarkets.com/research/g2...flammatory
Ischemic Stroke Drug Pipeline Report, H2 2013 Review
M2 - Wed Nov 06, 10:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/bpg5ck/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H2 2013" report to their offering. 'Ischemic Stroke - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ischemic Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ischemic Stroke. Scope - A snapshot of the global therapeutic scenario for Ischemic Stroke. - A review of the Ischemic Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ischemic Stroke pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned - Athersys, Inc. - Merck & Co., Inc. - FibroGen, Inc. - Laboratoires Pierre Fabre SA - Mitsubishi Tanabe Pharma Corporation - Pfizer Inc. - Celgene Corporation - Neuralstem, Inc. - Cytomedix, Inc. - Torrent Pharmaceuticals Limited - Pluristem Therapeutics Inc. - NeuroVive Pharmaceutical AB - SynZyme Technologies, LLC - AGY Therapeutics, Inc. - Angion Biomedica Corp. - Stemedica Cell Technologies, Inc. - Shin Poong Pharm Co., Ltd. For more information visit http://www.researchandmarkets.com/research/bp...mic_stroke
Psoriatic Arthritis Global Clinical Trials Review, H2 2013 Report
M2 - Tue Oct 15, 9:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5hllgq/psoriatic) has announced the addition of the "Psoriatic Arthritis Global Clinical Trials Review, H2, 2013" report to their offering. Psoriatic Arthritis Global Clinical Trials Review, H2, 2013 provides data on the Psoriatic Arthritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Psoriatic Arthritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Psoriatic Arthritis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Psoriatic Arthritis Therapeutics Clinical Trials - Pfizer Inc. - AbbVie Inc. - Celgene Corporation - Amgen Inc. - Centocor, Inc. - Janssen Biotech, Inc. - Novartis Pharmaceuticals Corporation - Merck & Co., Inc. - Bristol-Myers Squibb Company - Novartis AG - Janssen Research & Development, LLC - Janssen Pharmaceutica, Inc. - PanGenetics B.V. - LG Life Sciences, Ltd. - XOMA Corporation - Merck KGaA - EMD Serono, Inc. - Sandoz Inc. - Mitsubishi Tanabe Pharma Corporation - Astellas Pharma Inc. For more information visit http://www.researchandmarkets.com/research/5hllgq/psoriatic
Polio Global Clinical Trials Review - New 2013 Report
M2 - Mon Oct 14, 11:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/64r78x/polio_global) has announced the addition of the "Polio Global Clinical Trials Review, H2, 2013" report to their offering. Polio Global Clinical Trials Review, H2, 2013" provides data on the Polio clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Polio. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Polio. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Polio Therapeutics Clinical Trials - Baxter International - Bharat Biotech International Limited - Biolab Sanus Farmaceutica Ltda. - Daiichi Sankyo Company, Limited - GlaxoSmithKline - Laboratorios de Biologicos y Reactivos de Mexico, S.A de C.V. - Merck & Co., Inc. - Mitsubishi Tanabe Pharma Corporation - Panacea Biotec Limited - Pharmalink AB - Sanofi - Statens Serum Institut - Takeda Pharmaceutical Company Limited - ViroDefense Inc. For more information visit http://www.researchandmarkets.com/research/64...lio_global
Mitsubishi Tanabe Pharma Completes Acquisiton of Medicago
PR Newswire - Wed Sep 18, 6:50AM CDT
Mitsubishi Tanabe Pharma Corporation (TSE: 4508) ("Mitsubishi Tanabe Pharma" or "MTPC") and Medicago Inc. (TSX:MDG) announced today the completion of the previously announced acquisition of Medicago Inc. by MTPC.
Medicago Announces Receipt of Final Court Order and Regulatory Approvals for Arrangement with Mitsubishi Tanabe Pharma
PR Newswire - Thu Sep 12, 6:00AM CDT
Medicago Inc. (TSX: MDG; OTCQX: MDCGF) ("Medicago" or the "Company"), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), is pleased to announce that the Superior Court of Quebec has granted its final order approving the previously announced plan of arrangement (the "Arrangement") involving the Company, Mitsubishi Tanabe Pharma Corporation ("MTPC") and 9284-9686 Québec Inc., a wholly-owned subsidiary of MTPC (the "Purchaser").
Competitor Analysis: Poly-Adenyl-Ribose Polymerase (PARP) Inhibitors
M2 - Thu Sep 12, 3:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d2s635/competitor) has announced the addition of the "Competitor Analysis: Poly-Adenyl-Ribose Polymerase (PARP) Inhibitors" report to their offering. The present Competitive Intelligence report about Poly-Adenyl-Ribose Polymerase (PARP) Inhibitors provides a competitor evaluation in the field of small molecule inhibitors of Poly-Adenyl-Ribose Polymerase (PARP) for the treatment of solid tumors as of August 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. Poly(ADP-ribose) polymerases (PARPs) play a critical role in several pathways that repair DNA damage. Despite the recent failure of Sanofi's PARP inhibitor iniparib, presentation of results from clinical studies with other PARP inhibitors underlined continued interest in this emerging class of targeted cancer drug candidates. In fact, several companies are entering in clinical phase III evaluation of selective or dual/pan PARP inhibitors. The report includes a compilation of currently active projects in research and development of small molecule Poly-Adenyl-Ribose Polymerase (PARP) inhibitors in oncology. In addition, the report lists company-specific R&D pipelines of PARP inhibitors. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage - additional comments with a hyperlink leading to the source of information. Companies Mentioned - AbbVie - Angion Biomedica - AstraZeneca - BioMarin Pharmaceuticals - Clovis Oncology - Eisai - Eternity Bioscience - Inotek Pharmaceuticals - Mitsubishi Tanabe Pharma - Nerviano Medical Sciences - NewGen Therapeutics - Tesaro - Teva Pharmaceutical Industries For more information visit http://www.researchandmarkets.com/research/d2s635/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Obesity - Pipeline Review, H2 2013
M2 - Mon Sep 09, 5:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8nk97f/obesity) has announced the addition of the "Obesity - Pipeline Review, H2 2013" report to their offering. 'Obesity - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Obesity, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Obesity. Scope - A snapshot of the global therapeutic scenario for Obesity. - A review of the Obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Obesity pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Boehringer Ingelheim GmbH Shionogi & Co., Ltd. Amgen Inc. Sanofi-Aventis AstraZeneca PLC Eli Lilly and Company Athersys, Inc. GlaxoSmithKline plc Isis Pharmaceuticals, Inc. Merck & Co., Inc. Novo Nordisk A/S Takeda Pharmaceutical Company Limited Plexxikon Inc. BioLineRx, Ltd. Ipsen S.A. Chong Kun Dang Pharmaceutical Glenmark Pharmaceuticals Ltd. GTx, Inc. Kissei Pharmaceutical Co., Ltd. Mitsubishi Tanabe Pharma Corporation Norgine Limited and much more... For more information visit http://www.researchandmarkets.com/research/8nk97f/obesity About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Urinary Incontinence - Pipeline Review, H2 2013
M2 - Fri Sep 06, 2:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gnq99s/urinary) has announced the addition of the "Urinary Incontinence - Pipeline Review, H2 2013" report to their offering. 'Urinary Incontinence - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Urinary Incontinence, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Urinary Incontinence. Scope - A snapshot of the global therapeutic scenario for Urinary Incontinence. - A review of the Urinary Incontinence products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Urinary Incontinence pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Cook Medical Incorporated Allergan, Inc. Astellas Pharma Inc. Mitsubishi Tanabe Pharma Corporation Recordati S.p.A. Addex Pharmaceuticals Evotec Aktiengesellschaft Plethora Solutions Holdings plc Melior Discovery, Inc. Fate Therapeutics, Inc. Celogos Sinil Pharma Ltd. Beech Tree Labs, Inc. For more information visit http://www.researchandmarkets.com/research/gnq99s/urinary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013 comes Complete with Latest Updates
M2 - Thu Sep 05, 10:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kg6q26/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Amyotrophic Lateral Sclerosis. - A review of the Amyotrophic Lateral Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Amyotrophic Lateral Sclerosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Aeolus Pharmaceuticals, Inc. - Amorfix Life Sciences Ltd. - Biogen Idec Inc. - BrainStorm Cell Therapeutics Inc. - California Stem Cell, Inc. - Cellceutix Corporation - Ceregene, Inc. - Cytokinetics, Inc - D-Pharm Ltd. - Daval International Ltd. - Eisai Co., Ltd. - Genzyme Corporation - GlaxoSmithKline plc - Hadasit Medical Research Services & Development Ltd - Isis Pharmaceuticals, Inc. - Isotechnika Pharma Inc. - Jeil Pharmaceutical Co., Ltd. - KineMed, Inc. - Kringle Pharma, Inc. - M's Science Corporation - Maas Biolab - MediPost Co., Ltd. - miRagen Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuraltus Pharmaceuticals, Inc. - Neurimmune Therapeutics AG - NeuroNova AB - Nexgenix Pharmaceuticals, LLC - Novartis AG - Nutra Pharma Corporation - Oxford BioMedica plc - Paladin Labs Inc. - Pharmagenesis, Inc. - Pharnext SAS - Q Therapeutics, Inc. - Questcor Pharmaceuticals, Inc. - Reata Pharmaceuticals, Inc. - RhinoCyte, Inc. - SCYNEXIS, Inc. - Snowdon Inc. - Trophos SA - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/kg...myotrophic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Concise Analysis of the Future Prospects of Global Personalized Medicine Market
M2 - Tue Mar 04, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/zpctsr/future_prospects) has announced the addition of the "Concise Analysis of the Future Prospects of Global Personalized Medicine Market" report to their offering. Over the years, the Global Personalized Medicine market has been witnessing the emergence of various tools and technologies from the reputed vendors. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Further, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 for predicting the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Co. - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Danaher Corp. - Eli Lilly and Co. - Evotec AG - F. Hoffmann-La Roche Ltd. - GE Healthcare Ltd. - Genelex Corp. - GlaxoSmithKline plc - Hologic Inc. - Johnson & Johnson - Laboratory Corporation of America Holdings - Life Technologies Corp. - Merck KGaA - Mitsubishi Tanabe Pharma Corp. - Myriad Genetics Inc. - Novartis AG - Novartis AG - PerkinElmer Inc. - Pfizer Inc. - Pfizer Inc. - Quest Diagnostics Inc. - Sanofi S.A. - Sanofi S.A. - Siemens Healthcare - Sigma-Aldrich Corp. - Takeda Pharmaceutical Co. Ltd. - Teva Pharmaceutical Industries Ltd. - Thermo Fisher Scientific Inc. - Transgenomic Inc. For more information visit http://www.researchandmarkets.com/research/zp..._prospects
MediMabs Announces the Appointment of Two New Members of the Board of Directors
Marketwire - Thu Feb 20, 10:52AM CST
Ms. Sarita Benchimol, the President and Chief Executive Officer of MediMabs Inc., is pleased to announce the election to the MediMabs Board of Directors of Dr. Randal Chase PhD and Mr. R Martin Wong CPA, CA. Both individuals were elected at the company's shareholder meeting and will be joining the existing board of directors, which includes Dr. Phil Gold CC, OQ, MD, PhD, FRSCopyright, FRCPCopyright, MACP, Dr. Claudio Cuello OC, MD, DSc, FRSCopyright, Mr. Miguel Madanes Eng., and Ms. Sarita Benchimol MSc.
General Anxiety Disorder - Pipeline Review, H2 2013
M2 - Tue Jan 28, 3:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/45w2z8/general_anxiety) has announced the addition of the "General Anxiety Disorder - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for General Anxiety Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for General Anxiety Disorder. General Anxiety Disorder - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for General Anxiety Disorder. - A review of the General Anxiety Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the General Anxiety Disorder pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to Buy - Identify and understand important and diverse types of therapeutics under development for General Anxiety Disorder. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding General Anxiety Disorder pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - Edgemont Pharmaceuticals - H. Lundbeck - Mitsubishi Tanabe Pharma Corporation - Rottapharm|Madaus For more information visit http://www.researchandmarkets.com/research/45...al_anxiety About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Market Research: Depression - Pipeline Review, H2 2013
M2 - Fri Dec 06, 3:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/q2dd65/depression) has announced the addition of the "Depression - Pipeline Review, H2 2013" report to their offering. 'Depression - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Depression, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Depression. Scope - A snapshot of the global therapeutic scenario for Depression. - A review of the Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Depression pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH AstraZeneca PLC GlaxoSmithKline plc Daiichi Sankyo Company, Ltd Taisho Pharmaceutical Co., Ltd. Takeda Pharmaceutical Company Limited Neurocrine Biosciences, Inc. Aphios Corporation Eisai Co., Ltd. H Lundbeck A/S Mitsubishi Tanabe Pharma Corporation Pfizer Inc. Sigma-Tau S.p.A. Addex Pharmaceuticals FAES Farma SA Anavex Life Sciences Corp. Karo Bio KunWha Pharmaceutical Co., Ltd. Newron Pharmaceuticals S.p.A. M et P Pharma AG Angelini Group Domain Therapeutics For more information visit http://www.researchandmarkets.com/research/q2dd65/depression About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Market Research: Secondary Hyperparathyroidism - Pipeline Review, H2 2013
M2 - Tue Dec 03, 3:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/db8lm5/secondary) has announced the addition of the "Secondary Hyperparathyroidism - Pipeline Review, H2 2013" report to their offering. 'Secondary Hyperparathyroidism - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Secondary Hyperparathyroidism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Secondary Hyperparathyroidism. Scope - A snapshot of the global therapeutic scenario for Secondary Hyperparathyroidism. - A review of the Secondary Hyperparathyroidism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Secondary Hyperparathyroidism pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Secondary Hyperparathyroidism. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Amgen Inc. Nektar Therapeutics Astellas Pharma Inc. Mitsubishi Tanabe Pharma Corporation OPKO Health, Inc. NPS Pharmaceuticals, Inc. Deltanoid Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/db8lm5/secondary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Invokana (Type 2 Diabetes) - Forecast and Market Analysis to 2022
M2 - Thu Nov 28, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/wvj6kv/invokana_type_2) has announced the addition of the "Invokana (Type 2 Diabetes) - Forecast and Market Analysis to 2022" report to their offering. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians' efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs. On March 29, 2013, the FDA approved Johnson & Johnson's Invokana (canagliflozin), the first-to-the-US-market SGLT-2 inhibitor for treatment of type 2 diabetes. Invokana is in-licensed from Mitsubishi Tanabe Pharma. Invokana's mechanism of action employs the inhibition of SGLT-2, a low-affinity, high-capacity glucose cotransporter that is almost exclusively expressed in the kidney cortex. Inhibition of SGLT-2 has been shown to block the body's capacity to reabsorb glucose via the kidney, leading to glucose elimination in the urine and a reduction in blood glucose levels. Scope - Overview of type 2 diabetes, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Invokana including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Invokana for the top ten countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China. Reasons to Buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of Invokana performance Key Topics Covered 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Invokana (canagliflozin) 7 Appendix For more information visit http://www.researchandmarkets.com/research/wv...ana_type_2 About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Covagen and Tanabe Research Laboratories Expand Strategic Research Collaboration for Development of Bispecific FynomAbs
PR Newswire - Thu Nov 21, 12:30AM CST
Covagen and Tanabe Research Laboratories U.S.A, Inc. (TRL), a fully owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), today announced that they expanded their strategic research collaboration. MTPC and TRL have nominated a first bispecific FynomAb for formal preclinical development which triggered an undisclosed milestone payment. MTPC and TRL also exercised an option for a second bispecific FynomAb program based on the parties' research and licensing agreement signed in October 2012. Under the agreement, Covagen will use its proprietary Fynomer-antibody platform to generate bispecific antibodies (FynomAbs) against a second target pair selected by TRL and MTPC.
Inflammatory Bowel Disease - Pipeline Review, H2 2013
M2 - Tue Nov 19, 3:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/g29c7q/inflammatory) has announced the addition of the "Inflammatory Bowel Disease - Pipeline Review, H2 2013" report to their offering. 'Inflammatory Bowel Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Inflammatory Bowel Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease. Scope - A snapshot of the global therapeutic scenario for Inflammatory Bowel Disease. - A review of the Inflammatory Bowel Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Inflammatory Bowel Disease pipeline on the basis of route of administration and molecule type. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Inflammatory Bowel Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Inflammatory Bowel Disease pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Key Topics Covered: Introduction Inflammatory Bowel Disease Overview Therapeutics Development Companies Involved in Inflammatory Bowel Disease Therapeutics Development Inflammatory Bowel Disease - Therapeutics Assessment Drug Profiles Appendix Companies Mentioned - 4SC - AlbireoPharma - Addex Pharmaceuticals - Basilea Pharmaceutica - Biotec Pharmacon - Compugen - Emergent BioSolutions - Eisai - Ferring Pharmaceuticals - GlaxoSmithKline - Indus Biotech Private Limited - Inotek Pharmaceuticals - Jenrin Discovery - Johnson & Johnson - KYORIN Pharmaceutical - Karo Bio - Lycera - Morria Biopharmaceuticals - Mitsubishi Tanabe Pharma - N30 Pharmaceuticals - Nephrx Corporation - Ono Pharmaceutical - Onyx Pharmaceuticals - PepTcell Limited - Paratek Pharmaceuticals - RaQualia Pharma - Rigel Pharmaceuticals - Santarus, Inc. - Synergy Pharmaceuticals - TiGenix NV - Upsher-Smith Laboratories - VentiRx Pharmaceuticals - Ventria Bioscience - Vitae Pharmaceuticals - Zealand Pharma A/S - iCo Therapeutics For more information visit http://www.researchandmarkets.com/research/g2...flammatory
Ischemic Stroke Drug Pipeline Report, H2 2013 Review
M2 - Wed Nov 06, 10:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/bpg5ck/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H2 2013" report to their offering. 'Ischemic Stroke - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ischemic Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ischemic Stroke. Scope - A snapshot of the global therapeutic scenario for Ischemic Stroke. - A review of the Ischemic Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ischemic Stroke pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned - Athersys, Inc. - Merck & Co., Inc. - FibroGen, Inc. - Laboratoires Pierre Fabre SA - Mitsubishi Tanabe Pharma Corporation - Pfizer Inc. - Celgene Corporation - Neuralstem, Inc. - Cytomedix, Inc. - Torrent Pharmaceuticals Limited - Pluristem Therapeutics Inc. - NeuroVive Pharmaceutical AB - SynZyme Technologies, LLC - AGY Therapeutics, Inc. - Angion Biomedica Corp. - Stemedica Cell Technologies, Inc. - Shin Poong Pharm Co., Ltd. For more information visit http://www.researchandmarkets.com/research/bp...mic_stroke
Psoriatic Arthritis Global Clinical Trials Review, H2 2013 Report
M2 - Tue Oct 15, 9:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5hllgq/psoriatic) has announced the addition of the "Psoriatic Arthritis Global Clinical Trials Review, H2, 2013" report to their offering. Psoriatic Arthritis Global Clinical Trials Review, H2, 2013 provides data on the Psoriatic Arthritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Psoriatic Arthritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Psoriatic Arthritis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Psoriatic Arthritis Therapeutics Clinical Trials - Pfizer Inc. - AbbVie Inc. - Celgene Corporation - Amgen Inc. - Centocor, Inc. - Janssen Biotech, Inc. - Novartis Pharmaceuticals Corporation - Merck & Co., Inc. - Bristol-Myers Squibb Company - Novartis AG - Janssen Research & Development, LLC - Janssen Pharmaceutica, Inc. - PanGenetics B.V. - LG Life Sciences, Ltd. - XOMA Corporation - Merck KGaA - EMD Serono, Inc. - Sandoz Inc. - Mitsubishi Tanabe Pharma Corporation - Astellas Pharma Inc. For more information visit http://www.researchandmarkets.com/research/5hllgq/psoriatic
Polio Global Clinical Trials Review - New 2013 Report
M2 - Mon Oct 14, 11:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/64r78x/polio_global) has announced the addition of the "Polio Global Clinical Trials Review, H2, 2013" report to their offering. Polio Global Clinical Trials Review, H2, 2013" provides data on the Polio clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Polio. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Polio. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Polio Therapeutics Clinical Trials - Baxter International - Bharat Biotech International Limited - Biolab Sanus Farmaceutica Ltda. - Daiichi Sankyo Company, Limited - GlaxoSmithKline - Laboratorios de Biologicos y Reactivos de Mexico, S.A de C.V. - Merck & Co., Inc. - Mitsubishi Tanabe Pharma Corporation - Panacea Biotec Limited - Pharmalink AB - Sanofi - Statens Serum Institut - Takeda Pharmaceutical Company Limited - ViroDefense Inc. For more information visit http://www.researchandmarkets.com/research/64...lio_global
Mitsubishi Tanabe Pharma Completes Acquisiton of Medicago
PR Newswire - Wed Sep 18, 6:50AM CDT
Mitsubishi Tanabe Pharma Corporation (TSE: 4508) ("Mitsubishi Tanabe Pharma" or "MTPC") and Medicago Inc. (TSX:MDG) announced today the completion of the previously announced acquisition of Medicago Inc. by MTPC.
Medicago Announces Receipt of Final Court Order and Regulatory Approvals for Arrangement with Mitsubishi Tanabe Pharma
PR Newswire - Thu Sep 12, 6:00AM CDT
Medicago Inc. (TSX: MDG; OTCQX: MDCGF) ("Medicago" or the "Company"), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), is pleased to announce that the Superior Court of Quebec has granted its final order approving the previously announced plan of arrangement (the "Arrangement") involving the Company, Mitsubishi Tanabe Pharma Corporation ("MTPC") and 9284-9686 Québec Inc., a wholly-owned subsidiary of MTPC (the "Purchaser").
Competitor Analysis: Poly-Adenyl-Ribose Polymerase (PARP) Inhibitors
M2 - Thu Sep 12, 3:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d2s635/competitor) has announced the addition of the "Competitor Analysis: Poly-Adenyl-Ribose Polymerase (PARP) Inhibitors" report to their offering. The present Competitive Intelligence report about Poly-Adenyl-Ribose Polymerase (PARP) Inhibitors provides a competitor evaluation in the field of small molecule inhibitors of Poly-Adenyl-Ribose Polymerase (PARP) for the treatment of solid tumors as of August 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. Poly(ADP-ribose) polymerases (PARPs) play a critical role in several pathways that repair DNA damage. Despite the recent failure of Sanofi's PARP inhibitor iniparib, presentation of results from clinical studies with other PARP inhibitors underlined continued interest in this emerging class of targeted cancer drug candidates. In fact, several companies are entering in clinical phase III evaluation of selective or dual/pan PARP inhibitors. The report includes a compilation of currently active projects in research and development of small molecule Poly-Adenyl-Ribose Polymerase (PARP) inhibitors in oncology. In addition, the report lists company-specific R&D pipelines of PARP inhibitors. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage - additional comments with a hyperlink leading to the source of information. Companies Mentioned - AbbVie - Angion Biomedica - AstraZeneca - BioMarin Pharmaceuticals - Clovis Oncology - Eisai - Eternity Bioscience - Inotek Pharmaceuticals - Mitsubishi Tanabe Pharma - Nerviano Medical Sciences - NewGen Therapeutics - Tesaro - Teva Pharmaceutical Industries For more information visit http://www.researchandmarkets.com/research/d2s635/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Obesity - Pipeline Review, H2 2013
M2 - Mon Sep 09, 5:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8nk97f/obesity) has announced the addition of the "Obesity - Pipeline Review, H2 2013" report to their offering. 'Obesity - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Obesity, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Obesity. Scope - A snapshot of the global therapeutic scenario for Obesity. - A review of the Obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Obesity pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Boehringer Ingelheim GmbH Shionogi & Co., Ltd. Amgen Inc. Sanofi-Aventis AstraZeneca PLC Eli Lilly and Company Athersys, Inc. GlaxoSmithKline plc Isis Pharmaceuticals, Inc. Merck & Co., Inc. Novo Nordisk A/S Takeda Pharmaceutical Company Limited Plexxikon Inc. BioLineRx, Ltd. Ipsen S.A. Chong Kun Dang Pharmaceutical Glenmark Pharmaceuticals Ltd. GTx, Inc. Kissei Pharmaceutical Co., Ltd. Mitsubishi Tanabe Pharma Corporation Norgine Limited and much more... For more information visit http://www.researchandmarkets.com/research/8nk97f/obesity About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Urinary Incontinence - Pipeline Review, H2 2013
M2 - Fri Sep 06, 2:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gnq99s/urinary) has announced the addition of the "Urinary Incontinence - Pipeline Review, H2 2013" report to their offering. 'Urinary Incontinence - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Urinary Incontinence, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Urinary Incontinence. Scope - A snapshot of the global therapeutic scenario for Urinary Incontinence. - A review of the Urinary Incontinence products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Urinary Incontinence pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Cook Medical Incorporated Allergan, Inc. Astellas Pharma Inc. Mitsubishi Tanabe Pharma Corporation Recordati S.p.A. Addex Pharmaceuticals Evotec Aktiengesellschaft Plethora Solutions Holdings plc Melior Discovery, Inc. Fate Therapeutics, Inc. Celogos Sinil Pharma Ltd. Beech Tree Labs, Inc. For more information visit http://www.researchandmarkets.com/research/gnq99s/urinary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013 comes Complete with Latest Updates
M2 - Thu Sep 05, 10:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kg6q26/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Amyotrophic Lateral Sclerosis. - A review of the Amyotrophic Lateral Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Amyotrophic Lateral Sclerosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Aeolus Pharmaceuticals, Inc. - Amorfix Life Sciences Ltd. - Biogen Idec Inc. - BrainStorm Cell Therapeutics Inc. - California Stem Cell, Inc. - Cellceutix Corporation - Ceregene, Inc. - Cytokinetics, Inc - D-Pharm Ltd. - Daval International Ltd. - Eisai Co., Ltd. - Genzyme Corporation - GlaxoSmithKline plc - Hadasit Medical Research Services & Development Ltd - Isis Pharmaceuticals, Inc. - Isotechnika Pharma Inc. - Jeil Pharmaceutical Co., Ltd. - KineMed, Inc. - Kringle Pharma, Inc. - M's Science Corporation - Maas Biolab - MediPost Co., Ltd. - miRagen Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuraltus Pharmaceuticals, Inc. - Neurimmune Therapeutics AG - NeuroNova AB - Nexgenix Pharmaceuticals, LLC - Novartis AG - Nutra Pharma Corporation - Oxford BioMedica plc - Paladin Labs Inc. - Pharmagenesis, Inc. - Pharnext SAS - Q Therapeutics, Inc. - Questcor Pharmaceuticals, Inc. - Reata Pharmaceuticals, Inc. - RhinoCyte, Inc. - SCYNEXIS, Inc. - Snowdon Inc. - Trophos SA - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/kg...myotrophic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
(0)
(0)Mitsubishi Tanabe Ph (MTZXF) Stock Research Links
Scroll down for more posts ▼